2021 Fiscal Year Final Research Report
Development of new cancer treatment utilizing the enhancement of antitumor response caused by allo reaction
| Project/Area Number |
20K17649
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55020:Digestive surgery-related
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2022-03-31
|
| Keywords | がんワクチン / アロ反応 / NKT細胞 / 樹状細胞ワクチン / 同種異形樹状細胞 / 電気穿孔法 |
|---|
| Outline of Final Research Achievements |
This study shows the potential of a novel dendritic cell vaccine therapy in antitumor immunity, in which bone marrow-derived dendritic cells are electroporated with an exogenous ovalbumin protein and simultaneously pulsed with α-galactosylceramide. This strategy enhances the induction of cytotoxic CD8+ T cells specific for tumor-associated antigens through the activation of invariant natural killer T cells, natural killer cells, and intrinsic dendritic cells. Moreover, this strategy sustains antigen-specific antitumor T cell responses over time.
|
| Free Research Field |
消化器外科
|
| Academic Significance and Societal Importance of the Research Achievements |
免疫チェックポイント阻害剤の台頭と共に、奏功症例の解析が進み、がんの発症に伴う遺伝子変異に起因する新生変異抗原(neoantigen)の存在が必要条件であることが示された。ただ、neoantigenの同定は煩雑であり、共通性の極めて低いものであり、困難となる。 本研究は、neoantigenを同定せずとも免疫療法の機会を失しない、効果的なオーダーメイド治療の確立に貢献するものである。
|
